Interim / Quarterly Report • Oct 21, 2021
Interim / Quarterly Report
Open in ViewerOpens in native device viewer
JANUARY – SEPTEMBER 2021
Q3
2021
Net sales amounted to SEK 173.8 million (132.0), an increase of 32% (excluding foreign exchange effects, 35%)
Net sales in the Paediatrics segment reached SEK 130.8 million (101.9), an increase of 28%.
Net sales in the Adult Health segment amounted to SEK 42.1 million (29.3), an increase of 43%.
Operating expenses amounted to SEK 60.7 million (62.5), a decrease of 3%.
Operating profit increased by 148% to SEK 67.2 million (27.0), which corresponds to an operating margin of 39% (20%). Profit after tax amounted to SEK 52.8 million (20.5), an increase
of 158%. Earnings per share amounted to SEK 2.62 (1.17) before and after dilution.
Cash flow amounted to SEK 55.6 million (50.3).
Cash and cash equivalents at 30 September 2021 amounted to SEK 1,529.7 million (292.4).
On 2 July, BioGaia announced that the company had become the owner of 100% of the shares in MetaboGen. Previously, BioGaia owned 92% of the shares. The purchase price amounted to SEK 11.4 million.
On 10 September, BioGaia Pharma announced that it had received formal approval to proceed with both of its planned clinical trials. The trials represent the next phase in the development of BioGaia Pharma's two pharmaceutical candidates.
On 20 September, BioGaia announced that it will begin to sell its probiotic products under its own management in the UK market from November 2021. The decision is part of the company's overall strategy of increasing B2C sales and sales via its own e-commerce solution.
Net sales amounted to SEK 578.9 million (559.5), an increase of 3% (excluding foreign exchange effects, 12%)
Net sales in the Paediatrics segment reached SEK 453.6 million (443.5), an increase of 2%.
Net sales in the Adult Health segment amounted to SEK 121.7 million (113.9), an increase of 7%.
Operating expenses amounted to SEK 223.2 million (224.1), a decrease of 0.4%. Operating expenses included costs of evaluation of acquisition candidates of SEK 2.6 million and restructuring costs of SEK 7.5 million. Excluding these costs, operating expenses amounted to SEK 213.1 million, a decrease of 5%.
Operating profit increased by 10% to SEK 200.6 million (182.9), which corresponds to an operating margin of 35% (33%).
Profit after tax amounted to SEK 158.0 million (141.3), an increase of 12%.
Earnings per share amounted to SEK 7.82 (8.08) before and after dilution.
Cash flow amounted to SEK 56.7 million (79.0).
Cash and cash equivalents at 30 September 2021 amounted to SEK 1,529.7 million (292.4).
On 13 October, BioGaia announced that profit for the third quarter exceeded market expectations.
1) A bonus issue element from the 2020 new issue has been taken into account in the calculation of earnings per share before and after dilution, which means that comparative figures have been recalculated.
2) Key ratio defined according to IFRS. For definitions of other key ratios, see page 14.
This information is information that BioGaia AB is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the CEO, at 8:00 a.m. CEST on 21 October 2021.
BioGaia AB (publ) Interim management statement 1 January – 30 September 2021 The Board of Directors and the CEO of BioGaia AB hereby present the interim management statement for the period 1 January – 30 September 2021.
With sales of SEK 174 million (an increase of +32% and excluding foreign exchange effects an increase of +35%) and an operating profit of SEK 67 million, we are very pleased with the third quarter and the robust manner in which the organization has delivered. We can see three external reasons for the good result. Firstly, increased demand from consumers ahead of the winter season, with a focus on the immune system. Secondly, the lifting of pandemic restrictions has led to a rise in visits to doctors and pharmacies and thirdly, several markets, particularly in EMEA, have needed to replenish their inventories and requested that deliveries be moved forward from the fourth to the third quarter.
Following the establishment of BioGaia Japan in 2006 and BioGaia Finland at the beginning of this year, we are now ready to launch BioGaia UK in November. Our ambition with these "direct markets" is to be accessible in these highly interesting markets for probiotics where we previously lacked the right partners that could join us on our strategic journey to build the world's most respected probiotic brand. From November, consumers in the UK can buy BioGaia's complete product range on our own e-commerce platform and from mid-November from Amazon UK. We will thereafter gradually establish BioGaia in other parts of the UK market.
Elsewhere in the world, we are continuing our 32-year success story together with our partners. We are beginning to see the light at the end of the tunnel in EMEA (with sales growth of +51% compared with the year-earlier period) in Italy, Spain and Germany, where we launched "back to school" campaigns. APAC (with sales growth of +53% compared with the year-earlier period) has continued to make good progress in part due to our online ventures in China, our sales to dental surgeries and via our own e-commerce platform in Japan and positive demographic trends in Indonesia and Vietnam.
North America remains our strongest growth market due both to the launch of new products (Immune Boost and Prodentis Kids) and our omni-channel strategy whereby BioGaia is available in all consumer channels and through recommendations from the healthcare sector. Latin America noted a drop in sales for the quarter, primarily due to the accrual of orders in Brazil.
Our research companies are continuing research and development into the microbiome, where BioGaia Pharma has received approval for two clinical trials and MetaboGen is focusing on developing next-generation probiotics. In July, BioGaia acquired the remaining shares in MetaboGen and in the third quarter MetaboGen continued its clinical programmes.
To sum up, as the market for probiotics is growing worldwide, in terms of both sales and consumer awareness, life after the pandemic will lead to a greater focus on preventive healthcare. Based on these trends, together with our focus on global brand building and our omni-channel strategy, I remain convinced of our ability to grow.
Isabelle Ducellier President and CEO BioGaia 21 October 2021
BioGaia AB (publ) Interim management statement, January – September 2021 3 Teleconference: Investors, analysts and the media are invited to take part in a teleconference on the interim management statement to be held today, 21 October 2021, at 9:30 a.m. CEST with CEO Isabelle Ducellier and CFO Alexander Kotsinas. To participate in the teleconference, please call +46 8 505 583 53. More information about the teleconference is available here: https://financialhearings.com/event/13238
Q3
2021
| SEKm | Jul–Sep 2021 |
Jul–Sep 2020 |
Change | Jan–Sep 2021 |
Jan–Sep 2020 |
Change |
|---|---|---|---|---|---|---|
| Paediatrics | 130.8 | 101.9 | 28% | 453.6 | 443.5 | 2% |
| Adult Health | 42.1 | 29.3 | 43% | 121.7 | 113.9 | 7% |
| Other | 0.9 | 0.8 | 20% | 3.7 | 2.1 | 75% |
| Total | 173.8 | 132.0 | 32% | 578.9 | 559.5 | 3% |
| SEKm | Jul–Sep 2021 |
Jul–Sep 2020 |
Change | Jan–Sep 2021 |
Jan–Sep 2020 |
Change |
|---|---|---|---|---|---|---|
| EMEA | 87.0 | 57.7 | 51% | 250.8 | 289.1 | -13% |
| APAC | 44.0 | 28.7 | 53% | 141.2 | 116.5 | 21% |
| Americas | 42.9 | 45.5 | -6% | 187.0 | 153.8 | 22% |
| Total | 173.8 | 132.0 | 32% | 578.9 | 559.5 | 3% |
| Jan-Sep 2021 |
Jan-Sep 2020 |
Change |
|---|---|---|
| 453.6 | 443.5 | 2% |
| 121.7 | 113.9 | $7\%$ |
| 3.7 | 2.1 | 75% |
| 578.9 | 559.5 | 3% |
| Jan-Sep 2021 |
Jan-Sep 2020 |
Change |
|---|---|---|
| 250.8 | 289.1 | -13% |
| 141.2 | 116.5 | 21% |
| 187.0 | 153.8 | 22% |
| 578.9 | 559.5 | 3% |
Figures in parentheses refer to the corresponding period last year. Consolidated net sales amounted to SEK 173.8 million (132.0) which is an increase of SEK 41.8 million (32%) (excluding foreign exchange effects, 35%) compared to the third quarter of last year.
Sales in EMEA totalled SEK 87.0 million (57.7), up 51% mainly due to increased sales in the Paediatrics and Adult Health segments. Sales within Paediatrics increased primarily in Spain and Russia. The increase in Spain was mainly due to the accrual of individual orders towards the end of the quarter. The increase within Adult Health was primarily attributable to Eastern Europe and Germany.
Sales in APAC amounted to SEK 44.0 million (28.7), an increase of 53%. The increase was attributable to the Paediatrics and Adult Health segments. In the Paediatrics segment, sales increased mainly in China. In the Adult Health segment, sales increased mainly in China and Hong Kong.
Sales in the Americas amounted to SEK 42.9 million (45.5), a decrease of 6%, which was due to lower sales in the Paediatrics segment while sales in the Adult Health segment increased. The lower sales in Paediatrics were mainly attributable to Brazil, which was partly offset by healthy sales growth in the USA. The increase within Adult Health was primarily attributable to the USA.
| SEKm | Change | |
|---|---|---|
| 2020 | 132.0 | |
| Foreign exchange | -4.6 | -3% |
| Organic growth | 46.5 | 35% |
| 2021 | 173.8 | 32% |
Figures in parentheses refer to the corresponding period last year. Consolidated net sales amounted to SEK 578.9 million (559.5) which is an increase of SEK 19.4 million (3%) (excluding foreign exchange effects, 12%) compared to last year. Over the past 12-month period, sales changed by 0%.
Sales in EMEA amounted to SEK 250.8 million (289.1), a decrease of 13%, which was due to lower sales within Paediatrics and Adult Health.
The lower sales within Paediatrics were mainly attributable to Italy and parts of Eastern Europe. The lower sales within Adult Health were mainly attributable to Italy and Finland.
Sales in APAC totalled SEK 141.2 million (116.5), an increase of 21% due to increased sales within Paediatrics and Adult Health. Sales within Adult Health increased primarily in Japan, China and Hong Kong. In the Paediatrics segment, sales increased mainly in Australia, Vietnam and China.
Sales in the Americas totalled SEK 187.0 million (153.8), an increase of 22%, which was due to higher sales in the Paediatrics and Adult Health segments. The increased sales within both segments were mainly attributable to the USA.
| SEKm | Change | |
|---|---|---|
| 2020 | 559.5 | |
| Foreign exchange | -47.2 | -8.4% |
| Organic growth | 66.6 | 11.9% |
| 2021 | 578.9 | 3.5% |
The Paediatrics segment accounts for approximately 80% of BioGaia's total sales. BioGaia Protectis drops remain the largest product with sales in more than 90 countries. Other key products within Paediatrics include BioGaia Protectis drops with vitamin D, oral rehydration solution and tablets as well as cultures to be used as ingredients in licensee products (such as infant formula) and royalty revenues for paediatric products.
| SEKm | Jul–Sep 2021 |
Jul–Sep 2020 |
Change | Jan–Sep 2021 |
Jan–Sep 2020 |
Change |
|---|---|---|---|---|---|---|
| Products | 128.9 | 98.2 | 31% | 447.6 | 433.2 | 3% |
| Royalties | 1.9 | 3.6 | -47% | 5.9 | 10.3 | -42% |
| Total | 130.8 | 101.9 | 28% | 453.6 | 443.5 | 2% |
| Change | Jan-Sep | Jan-Sep |
|---|---|---|
| 2020 | 2021 | |
| 3% | 433.2 | 447.6 |
| $-42%$ | 10.3 | 59 |
| 2% | 443.5 | 453.6 |
Figures in parentheses refer to the corresponding period last year. Sales in the Paediatrics segment amounted to SEK 130.8 million (101.9), an increase of 28% (excluding foreign exchange effects, 32%).
Sales of BioGaia Protectis drops increased in all regions except in the Americas compared to the corresponding period last year. In EMEA, sales of drops increased primarily in Spain and Russia. In APAC, sales increased primarily in China and Indonesia. In the Americas, sales decreased primarily in Brazil, which was partly offset by favourable sales growth in the USA.
Sales of BioGaia Protectis tablets within Paediatrics decreased in all regions compared to the corresponding period last year. The decrease was primarily due to lower sales in Brazil and Eastern Europe.
Figures in parentheses refer to the corresponding period last year. Sales in the Paediatrics segment amounted to SEK 453.6 million (443.5), an increase of 2% (excluding foreign exchange effects, 11%). Over the past 12-month period, sales changed by -1%.
Sales of BioGaia Protectis drops increased compared to the corresponding period last year. Sales increased in APAC and the Americas, but decreased in EMEA. Sales in APAC increased primarily in Vietnam and Australia. In the Americas, sales increased mainly in the USA, which were partly offset by a decrease in sales, particularly in Brazil. In EMEA, sales of drops decreased primarily in Italy and Eastern Europe, while sales increased particularly in Russia and France.
Sales of BioGaia Protectis tablets decreased within Paediatrics compared to the corresponding period last year. The decrease was due to lower sales in all regions, primarily in Eastern Europe, Spain and Brazil.
The Adult Health segment accounts for approximately 20% of BioGaia's total sales. Sales mainly comprise BioGaia Protectis, BioGaia Gastrus, BioGaia Prodentis and BioGaia Osfortis as well as cultures as an ingredient in a licensee's dairy products.
| SEKm | Jul–Sep 2021 |
Jul–Sep 2020 |
Change | Jan–Sep 2021 |
Jan–Sep 2020 |
Change |
|---|---|---|---|---|---|---|
| Products | 39.2 | 26.9 | 46% | 105.5 | 106.1 | -1% |
| Royalties | 2.9 | 2.4 | 20% | 16.2 | 7.8 | 108% |
| Total | 42.1 | 29.3 | 43% | 121.7 | 113.9 | 7% |
| Jan-Sep | Jan-Sep | Change |
|---|---|---|
| 2021 | 2020 | |
| 105.5 | 106.1 | $-1%$ |
| 16.2 | 7.8 | 108% |
| 121.7 | 113.9 | 7% |
Figures in parentheses refer to the corresponding period last year. Sales in the Adult Health segment amounted to SEK 42.1 million (29.3), an increase of 43% (excluding foreign exchange effects, 47%).
Sales of BioGaia Protectis tablets increased in APAC and the Americas compared to the corresponding period last year. In APAC, sales increased primarily in Hong Kong and in the Americas sales increased mainly in the USA and Mexico. In EMEA, sales decreased mainly in Belgium and Finland.
Sales of BioGaia Gastrus increased in all regions compared to the corresponding period last year. Sales increased primarily in the USA, Japan and China.
Sales of BioGaia Prodentis increased in EMEA and the Americas compared to the corresponding period last year. Sales increased mainly in Germany, which were partly offset by a decrease in sales in APAC, particularly in Japan and Korea.
Figures in parentheses refer to the corresponding period last year. Sales in the Adult Health segment amounted to SEK 121.7 million (113.9), an increase of 7% (excluding foreign exchange effects, 15%). Over the past 12-month period, sales rose 3%.
Sales of BioGaia Protectis tablets decreased compared to the corresponding period last year. Sales decreased in EMEA while they increased in APAC and the Americas. In EMEA, sales decreased mainly in Italy, Belgium and Finland. In APAC, sales increased primarily in Hong Kong, and in the Americas sales increased mainly in the USA.
Sales of BioGaia Gastrus increased compared to the corresponding period last year. Sales increased in EMEA and APAC and decreased in the Americas.
In EMEA, sales increased mainly in France. In APAC, sales increased primarily in China while sales in the Americas decreased mainly in Mexico.
Sales of BioGaia Prodentis increased compared to the corresponding period last year. In EMEA, sales increased mainly in France and in the Americas primarily in Mexico. In APAC, sales decreased mainly in Japan and Korea.
Q3
2021
Figures in parentheses refer to the corresponding period last year. The total gross margin for the quarter amounted to 74% (68%). The gross margin for the Paediatrics segment amounted to 75% (66%). The gross margin for the Adult Health segment amounted to 67% (72%). The higher gross margin is primarily due to increased sales of BioGaia Protectis drops. The lower gross margin for the Adult Health segment is primarily the result of mix effects and campaigns.
Operating expenses amounted to SEK 60.7 million (62.5), a decrease of SEK 1.8 million. Excluding other operating expenses (exchange losses/gains) operating expenses increased by 12%.
Selling expenses amounted to SEK 38.6 million (32.9), an increase of 17%, mainly due to increased marketing activities and higher personnel costs.
R&D expenses amounted to SEK 19.7 million (19.8), a decrease of 0.3%. R&D expenses include costs for the subsidiaries MetaboGen AB and BioGaia Pharma AB of SEK 4.3 million (5.7).
Administrative expenses amounted to SEK 7.0 million (5.4), an increase of 29%, mainly due to higher personnel costs.
Other operating expenses refers to exchange losses/gains on receivables and liabilities of an operating nature and amounted to SEK -4.6 million (4.3).
Operating profit amounted to SEK 67.2 million (27.0), an increase of 148%. The operating margin was 39% (20%).
Profit after tax and earnings per share
Profit after tax amounted to SEK 52.8 million (20.5), an increase of 158%. The effective tax rate was 21% (24%).
Earnings per share amounted to SEK 2.62 (1.17) before and after dilution.
Gross margin
Figures in parentheses refer to the corresponding period last year. The total gross margin amounted to 73% (73%). The gross margin for the Paediatrics segment amounted to 75% (73%). The gross margin for the Adult Health segment amounted to 66% (70%).
Operating expenses and operating profit
Operating expenses amounted to SEK 223.3 million (224.1), a decrease of SEK 0.8 million. Excluding other operating expenses (exchange losses/gains) operating expenses increased by 7%.
Selling expenses amounted to SEK 125.8 million (122.0), an increase of 3%.
R&D expenses amounted to SEK 75.0 million (75.0), a change of 0%. R&D expenses include costs for the subsidiaries MetaboGen AB and BioGaia Pharma AB of SEK 17.0 million (18.5).
Administrative expenses amounted to SEK 30.4 million (18.9), an increase of 61%. The increase in administrative expenses is mainly attributable to increased costs for evaluation of acquisition candidates (SEK 2.6 million), impairment of right-of-use assets linked to a rental contract for premises in Lund (SEK 5.1 million) and increased personnel costs related to reorganisation.
Other operating expenses refers to exchange losses/gains on receivables and liabilities of an operating nature and amounted to SEK -7.9 million (8.2). Operating profit amounted to SEK 200.6 million (182.9), an increase of 10%. The operating margin was 35% (33%).
Profit after tax and earnings per share
Profit after tax amounted to SEK 158.0 million (141.3), an increase of 12%. The effective tax rate was 21% (23%).
Earnings per share amounted to SEK 7.82 (8.08) before and after dilution.
The Parent Company's net sales amounted to SEK 545.5 million (532.6) and profit before tax was SEK 172.1 million (160.0). The financial performance of the Parent Company is in all material respects in line with that of the Group.
Total assets amounted to SEK 1,967.7 million (711.9). The increase is mainly explained by the new issue carried out in the fourth quarter of 2020.
Since year-end 2020, trade receivables have increased while inventories and trade payables have decreased. Financial assets have increased due to the acquisition of shares in Boneprox AB and Skinome AB.
In accordance with a resolution at the Annual General Meeting, BioGaia has introduced an incentive programme and issued subscription warrants, which resulted in an increase in equity by SEK 5.0 million.
Cash flow amounted to SEK 55.6 million (50.3) for the quarter.
Cash flow from operating activities amounted to SEK 68.0 million (55.4). The increase in cash flow in operations compared with the year-earlier period is due to higher operating profit while change in working capital has a negative impact.
Investments in property, plant and equipment amounted to SEK 1.4 million (3.0). Depreciation and impairment amounted to SEK 6.3 million (5.1). Investments in financial assets of SEK 11.4 million relate to the settlement of the additional purchase price for Metabogen.
Cash and cash equivalents at 30 September 2021 amounted to SEK 1,529.7 million (292.4).
Cash flow amounted to SEK 56.7 million (79.0). Cash flow includes a dividend of SEK 68.9 million (65.0) as well as a provision to the Foundation to Prevent Antibiotic Resistance of SEK 2.8 million (2.8). Cash flow from operating activities is marginally lower than the corresponding period last year.
Investments in property, plant and equipment amounted to SEK 3.2 million (14.1). Depreciation and impairment amounted to SEK 22.1 million (14.8) and include an impairment of SEK 5.1 million relating to restructuring in the first quarter. Investments in financial assets of SEK 33.7 million relate to the settlement of the additional purchase price for MetaboGen AB and the acquisition of shares in Boneprox AB and Skinome AB in conjunction with the establishment of BioGaia Invest AB.
The number of employees in the Group at 30 September 2021 totalled 159 (160 at 30 September 2020).
The company has an incentive programme for all employees based partly on the company's sales and profit and partly on qualitative targets. The maximum bonus is equal to 12% of salary. In addition to this programme, BioGaia has also implemented a subscription warrants programme as resolved by the 2021 Annual General Meeting. The programme involves the issue of a maximum of 365,000 warrants where each warrant shall entitle the holder during the period from 6 July 2024 through 6 November 2024 to subscribe for one new Class B share in BioGaia for a subscription price per share that amounts to SEK 578.2. The employees have been invited to purchase the warrants at an amount of SEK 55.6 which is the market value determined by an external valuation expert. A total of 89,730 warrants have been subscribed for, which results in additional equity injection of SEK 5.0 million and a possible dilution of existing shareholders of 0.4%. The programme also includes a stay-on bonus extending over a three-year period. For other terms and conditions relating to the programme, see the Board's proposal to the Annual General Meeting with appendices.
BioGaia's goal is to create strong value growth and a good return for the shareholders. This will be achieved through a greater emphasis
on the BioGaia brand, online sales, increased sales to both existing and new customers and a controlled cost level.
The long-term financial target is an operating margin (operating profit in relation to sales) of at least 34% with continued strong growth and increased investments in research, product development, brand building and the sales organisation. BioGaia's dividend policy is to pay a shareholder dividend equal to 50% of profit after tax in the Parent Company.
In view of the company's strong portfolio consisting of an increased number of innovative products that are sold predominantly under the BioGaia brand, successful clinical trials and an expanding distribution network that covers a large share of the key markets, BioGaia's future outlook remains bright.
Significant risks and uncertainties are described in the administration report of the annual report for 2020 on pages 52 and 53 and in Notes 27 and 28. No significant changes in these risks and uncertainties are assessed to have taken place at 30 September 2021 except for the impact of the Covid-19 pandemic as set out below.
The third quarter of 2021 continued to be marked by the Covid-19 pandemic and its impact on the world at large and on BioGaia. In most of the countries in which BioGaia operates, medical marketing is still the main business model. Due to the Covid-19 situation, our distributors' sales forces have not been able to visit doctors and pharmacy staff, which are our key target groups for medical marketing, to the same extent as previously. Furthermore, long-term lockdowns in many countries have meant that consumers have had limited opportunities to visit the principal sales channels for our products – physical pharmacies, hospitals and, in Japan, dental surgeries.
BioGaia has adapted to the current situation and changed how the company works with marketing and sales. For example, BioGaia has not been able to take part in international fairs and symposia, since these have been cancelled, but has instead focused on supporting its partners with marketing material that can be used online. Furthermore, BioGaia's employees have not been able to visit customers face-to-face but have used telephone and video meetings. BioGaia has not carried out any staff reductions or layoffs due to the pandemic. Nor has BioGaia taken part in any support programme with the exception of a government stimulus programme in Japan.
BioGaia has a strong financial position but a prolonged pandemic can even have a negative impact on a stable company such as BioGaia. A deterioration in the financial position and ability to pay of our distribution partners can lead to longer payment times but also credit losses. Furthermore, disruptions in BioGaia's production and at external suppliers or in logistics can result in BioGaia being unable to deliver products with an ensuing loss of revenue. Depending on how drawn-out this pandemic becomes, there is a risk of continued challenges in 2021.
The Parent Company owns 100% of the shares in BioGaia UK Ltd, BioGaia Finland Oy, BioGaia Invest AB, MetaboGen AB, BioGaia Biologics Inc. USA, BioGaia Japan Inc, BioGaia Production AB, CapAble AB and Tripac AB. The Parent Company also owns 96% of the shares in BioGaia Pharma AB.
Annwall & Rothschild Investment AB owns 740,668 class A shares and 100,000 class B shares, corresponding to 4.2% of the share capital and 27.9% of the voting rights in BioGaia AB. Annwall & Rothschild Investment AB is owned by Peter Rothschild and Jan Annwall. Peter Rothschild is Chairman of the Board of BioGaia AB and receives a director's fee of SEK 670,000 per year. During the quarter, Peter Rothschild received additional remuneration for significant working duties, in addition to his assignment on the Board, of SEK 150,000 in accordance with the decision of the
Annual General Meeting and the Board of Directors. In addition, a dividend of SEK 3.75 per share was paid to Annwall & Rothschild Investment AB during the period. Out of the total of 89,730 warrants subscribed in conjunction with the incentive programme described above, 84,750 were subscribed for by Executive Management including the CEO.
Launches in the third quarter of 2021
| Distributor | Country | Product |
|---|---|---|
| BioGaia | Finland | BioGaia Protectis drops and tablets, BioGaia Gastrus and BioGaia Prodentis |
| Sued | Dominican Republic |
BioGaia Protectis drops with vitamin D |
| Nestlé | Ecuador | Protectis Minipack |
| Nestlé | Ecuador | B. lactis drops |
| Everidis | USA | BioGaia Immun drops, tablets and capsules |
| Everidis | USA | BioGaia Prodentis Baby drops |
| Sunflower | China | BioGaia Prodentis Mum |
| Sunflower | China | BioGaia Prodentis Mini |
| BioGaia | China | BioGaia Osfortis |
| Grace International |
South Korea | BioGaia Protectis capsules |
| Grace International |
South Korea | BioGaia Protectis tablets with vitamin D |
| Cube | Greece | BioGaia Prodentis with new flavour (apple) |
BioGaia owns 100% of the shares in MetaboGen. On 2 July, BioGaia announced that the company had become the owner of 100% of the shares in MetaboGen. Previously, BioGaia owned 92% of the shares. The purchase price amounted to SEK 11,441,439 and is recognised in the half-year financial statements as a current liability to be settled in July.
BioGaia Pharma receives formal approval to proceed with both of its planned clinical trials. On 10 September, BioGaia Pharma announced that it had received formal approval to proceed with both of its planned clinical trials. The trials represent the next phase in the development of BioGaia Pharma's two pharmaceutical candidates. Enrolment will begin at the end of 2021.
BioGaia starts its own distribution in the UK. On 20 September, BioGaia announced that it will begin to sell its probiotic products under its own management in the UK market from November 2021. The decision is part of the company's overall strategy of increasing B2C sales and sales via its own e-commerce solution. BioGaia will launch its entire product portfolio in the British market.
On 13 October, BioGaia announced that profit for the third quarter exceeded market expectations.
In all material respects, this interim management statement has been prepared in accordance with Nasdaq OMX Stockholm's Guidelines for preparing interim management statements. Disclosures according to IAS 34 Interim Financial Reporting are provided both in notes and elsewhere in the interim management statement. The accounting policies applied in the consolidated statements of comprehensive income and financial position are consistent with the accounting policies applied in preparation of the most recent annual report.
The financial statements and segment information are consistent with the presentation used in the interim reports presented in compliance with IAS 34, in order to achieve comparability in presentation between quarters. The interim management statement contains, among other things, comments from the CEO, although this is not required according to Nasdaq OMX Stockholm's Guidelines for preparing interim management statements. This information is nonetheless considered important in meeting the users' needs.
Management's assessment is that new and amended standards and interpretations will not have a material effect on the Group's financial statements for the period of initial application.
| (Amounts in SEK 000s) | Jul–Sep | Jul–Sep | Jan–Sep | Jan–Sep | Jan–Dec | Oct 2020– | Oct 2019– |
|---|---|---|---|---|---|---|---|
| 2021 | 2020 | 2021 | 2020 | 2020 | Sep 2021 | Sep 2020 | |
| Net sales (Note 1) | 173,841 | 131,961 | 578,947 | 559,467 | 747,077 | 766,557 | 767,083 |
| Cost of sales | -45,975 | -42,458 | -155,032 | -152,513 | -200,159 | -202,678 | -205,945 |
| Gross profit | 127,866 | 89,503 | 423,915 | 406,954 | 546,918 | 563,879 | 561,138 |
| Selling expenses | -38,556 | -32,911 | -125,831 | -121,961 | -171,634 | -175,504 | -177,555 |
| Administrative expenses | -7,011 | -5,435 | -30,389 | -18,901 | -26,128 | -37,616 | -25,784 |
| Research and development expenses | -19,718 | -19,776 | -74,988 | -75,029 | -104,663 | -104,622 | -98,544 |
| Other operating expenses/income | 4,598 | -4,339 | 7,940 | -8,163 | -16,343 | -240 | -8,249 |
| Operating profit | 67,179 | 27,042 | 200,647 | 182,900 | 228,150 | 245,897 | 251,006 |
| Financial income | 1 | 37 | 64 | 109 | 155 | 110 | 261 |
| Financial expenses | -239 | -181 | -633 | -562 | -722 | -793 | -614 |
| Profit before tax | 66,941 | 26,898 | 200,078 | 182,447 | 227,583 | 245,214 | 250,653 |
| Tax | -14,097 | -6,415 | -42,080 | -41,184 | -47,853 | -48,749 | -56,824 |
| Profit for the period | 52,844 | 20,483 | 157,998 | 141,263 | 179,730 | 196,465 | 193,829 |
| Items that may be subsequently reclassified to profit or loss Gains/losses arising on translation of the statements of foreign |
|||||||
| operations | 965 | -311 | 1,250 | -3,767 | -4,059 | 958 | -3,559 |
| Comprehensive income for the period | 53,809 | 20,172 | 159,248 | 137,496 | 175,671 | 197,423 | 190,270 |
| Profit for the period attributable to: | |||||||
| Owners of the Parent Company | 52,844 | 20,483 | 157,998 | 141,263 | 179,730 | 196,465 | 193,811 |
| Non-controlling interests | - | - | - | - | - | - | 18 |
| 52,844 | 20,483 | 157,998 | 141,263 | 179,730 | 196,465 | 193,829 | |
| Comprehensive income for the period attributable to: | |||||||
| Owners of the Parent Company | 53,809 | 20,172 | 159,248 | 137,496 | 175,671 | 197,423 | 190,252 |
| Non-controlling interests | - | - | - | - | - | - | 18 |
| 190,270 | |||||||
| 53,809 | 20,172 | 159,248 | 137,496 | 175,671 | 197,423 | ||
| Earnings per share Earnings per share before dilution, (SEK) *) |
2.62 | 1.17 | 7.82 | 8.08 | 10.07 | 9.87 | 11.09 |
| Earnings per share after dilution, (SEK) *) | 2.62 | 1.17 | 7.82 | 8.08 | 10.07 | 9.87 | 11.09 |
| Number of shares (thousands) Average number of shares before dilution, (thousands) *) |
20,196 20,196 |
17,336 17,474 |
20,196 20,196 |
17,336 17,474 |
20,196 17,855 |
20,196 19,897 |
17,336 17,474 |
| Average number of shares after dilution, (thousands) *) | 20,196 | 17,474 | 20,196 | 17,474 | 17,855 | 19,897 | 17,474 |
*) A bonus issue element from the 2020 new issue has been taken into account in the calculation of earnings per share before and after dilution, which means that comparative figures have been recalculated.
Q3
2021
| Summary (Amounts in SEK 000s) | 30 Sep | 30 Sep | 31 Dec |
|---|---|---|---|
| 2021 | 2020 | 2020 | |
| ASSETS | |||
| Property, plant and equipment | 127,121 | 135,166 | 133,904 |
| R&D projects in progress | 48,645 | 50,881 | 50,322 |
| Goodwill | 5,300 | 5,300 | 5,300 |
| Right-of-use assets | 16,599 | 14,515 | 28,861 |
| Financial assets | 22,229 | - | - |
| Deferred tax assets | 4,944 | 5,040 | 5,279 |
| Other non-current receivables | 42 | 44 | 39 |
| Total non-current assets | 224,880 | 210,946 | 223,705 |
| Current assets excl. cash and cash equivalents | 213,072 | 208,536 | 221,694 |
| Cash and cash equivalents | 1,529,736 | 292,385 | 1,467,883 |
| Total current assets | 1,742,808 | 500,921 | 1,689,577 |
| TOTAL ASSETS | 1,967,688 | 711,867 | 1,913,282 |
| EQUITY AND LIABILITIES | |||
| Equity attributable to owners of the Parent Company | 1,838,810 | 577,558 | 1,746,243 |
| Non-controlling interests | 2 | 2 | 2 |
| Total equity (Note 2) | 1,838,812 | 577,560 | 1,746,245 |
| Deferred tax liability | 11,218 | 10,339 | 11,312 |
| Non-current liabilities | 13,601 | 17,839 | 20,663 |
| Current liabilities | 104,057 | 106,129 | 135,062 |
| TOTAL LIABILITIES AND EQUITY | 1,967,688 | 711,867 | 1,913,282 |
Other current liabilities include forward exchange contracts with a fair value of SEK 0 million on the balance sheet date (SEK 0.3 million in the corresponding period in the previous year). All forward exchange contracts are attributable to level 2 of the fair value hierarchy. No changed assumptions with regard to measurement have taken place compared to the 2020 Annual Report. The fair values of other receivables, cash and cash equivalents, trade payables and other liabilities are estimated to be equal to their carrying amounts (amortised cost) due to the short maturity.
| Jul–Sep | Jul–Sep | Jan–Sep | Jan–Sep | Jan–Dec | |
|---|---|---|---|---|---|
| Summary (Amounts in SEK 000s) | 2021 | 2020 | 2021 | 2020 | 2020 |
| Operating activities | |||||
| Operating profit | 67,179 | 27,042 | 200,647 | 182,900 | 228,150 |
| Depreciation/amortisation and impairment | 6,251 | 5,053 | 22,106 | 14,845 | 20,530 |
| Unrealised gains/losses on forward contracts | 296 | -548 | 2,403 | -2,816 | -4,876 |
| Other non-cash items | -4,496 | 383 | -5,189 | 195 | 1,167 |
| Paid tax | -16,851 | -17,117 | -52,731 | -51,967 | -72,092 |
| Interest received and paid | -238 | -143 | -569 | -452 | -646 |
| Cash flow from operating activities before changes in working | |||||
| capital | 52,141 | 14,670 | 166,667 | 142,705 | 172,233 |
| Changes in working capital | 15,814 | 40,755 | -1,057 | 23,936 | 49,023 |
| Cash flow from operating activities | 67,955 | 55,425 | 165,610 | 166,641 | 221,256 |
| Acquisition of property, plant and equipment | -1,383 | -2,978 | -3,195 | -14,084 | -16,075 |
| Acquisition of financial assets | -11,441 | - | -33,670 | - | - |
| Cash flow from investing activities | -12,824 | -2,978 | -36,865 | -14,084 | -16,075 |
| Dividend | - | - | -68,870 | -65,012 | -65,012 |
| Repayment of lease liability | -2,370 | -2,117 | -5,389 | -5,746 | -7,632 |
| Provision to Foundation to Prevent Antibiotic Resistance | - | - | -2,800 | -2,800 | -2,800 |
| New share issue | - | - | - | - | 1,126,840 |
| Issue of warrants | 2,851 | 4,989 | - | ||
| Cash flow from financing activities | 481 | -2,117 | -72,070 | -73,558 | 1,051,396 |
| Cash flow for the period | 55,612 | 50,330 | 56,675 | 78,999 | 1,256,577 |
| Cash and cash equivalents at the beginning of the period | 1,468,935 | 242,546 | 1,467,883 | 213,831 | 213,831 |
| Exchange difference in cash and cash equivalents | 5,189 | -491 | 5,178 | -445 | -2,525 |
| Cash and cash equivalents at the end of the period | 1,529,736 | 292,385 | 1,529,736 | 292,385 | 1,467,883 |
BioGaia AB (publ) Interim management statement, January – September 2021 11
Executive Management has analysed the Group's internal reporting and determined that the Group's operations are monitored and evaluated based on the following segments:
– Paediatrics segment (drops, gut health tablets, oral rehydration solution (ORS) and cultures to be used as ingredients in licensee products (such as infant formula) as well as royalty revenues for paediatric products.
– Adult Health segment (gut health tablets, oral health lozenges and cultures as an ingredient in a licensee's dairy products as well as royalty revenues for Adult Health products.
– Other segment (smaller segments such as royalty from development projects).
For the above segments BioGaia reports revenue and gross profit, which are monitored regularly by the CEO (who is regarded as the chief operating decision maker) together with the Executive Management. There is no monitoring of the company's total assets and liabilities against the segments' assets.
| (Amounts in SEK 000s) | Jul–Sep | Jul–Sep | Jan–Sep | Jan–Sep | Jan–Dec | Oct 2020– | Oct 2019– |
|---|---|---|---|---|---|---|---|
| Revenue by segment | 2021 | 2020 | 2021 | 2020 | 2020 | Sep 2021 | Sep 2020 |
| Paediatrics | 130,830 | 101,854 | 453,581 | 443,497 | 583,111 | 593,195 | 600,875 |
| Adult Health | 42,089 | 29,341 | 121,694 | 113,877 | 161,186 | 169,003 | 163,797 |
| Other | 922 | 766 | 3,672 | 2,093 | 2,780 | 4,359 | 2,412 |
| Total | 173,841 | 131,961 | 578,947 | 559,467 | 747,077 | 766,557 | 767,084 |
| Gross profit by segment | |||||||
| Paediatrics | 98,556 | 67,610 | 340,280 | 325,366 | 431,810 | 446,725 | 444,980 |
| Adult Health | 28,389 | 21,127 | 79,963 | 79,684 | 112,588 | 112,866 | 113,935 |
| Other | 921 | 766 | 3,672 | 1,904 | 2,521 | 4,288 | 2,223 |
| Total | 127,866 | 89,503 | 423,915 | 406,954 | 546,918 | 563,879 | 561,138 |
| Selling, administrative and R&D expenses | -65,285 | -58,122 | -231,208 | -215,891 | -302,425 | -317,742 | -301,883 |
| Other operating expenses | 4,598 | -4,339 | 7,940 | -8,163 | -16,343 | -240 | -8,249 |
| Operating profit | 67,179 | 27,042 | 200,647 | 182,900 | 228,150 | 245,897 | 251,006 |
| Net financial items | -238 | -144 | -569 | -453 | -567 | -683 | -353 |
| Profit before tax | 66,941 | 26,898 | 200,078 | 182,447 | 227,583 | 245,214 | 250,653 |
| Sales by geographical market | |||||||
| APAC | |||||||
| Paediatrics | 21,719 | 9,484 | 68,686 | 59,694 | 82,689 | 91,681 | 79,254 |
| Adult Health | 21,620 | 18,804 | 70,926 | 55,862 | 86,625 | 101,689 | 91,278 |
| Other | 659 | 429 | 1,541 | 982 | 1,432 | 1,991 | 1,043 |
| Total APAC | 43,998 | 28,717 | 141,153 | 116,538 | 170,746 | 195,361 | 171,575 |
| EMEA | |||||||
| Paediatrics | 73,325 | 48,892 | 214,294 | 241,770 | 312,520 | 285,044 | 338,875 |
| Adult Health | 13,385 | 8,519 | 34,486 | 46,377 | 58,894 | 47,003 | 56,077 |
| Other | 240 | 311 | 2,049 | 948 | 1,169 | 2,270 | 1,205 |
| Total EMEA | 86,950 | 57,722 | 250,829 | 289,095 | 372,583 | 334,317 | 396,157 |
| Americas | |||||||
| Paediatrics | 35,787 | 43,478 | 170,601 | 142,033 | 187,902 | 216,470 | 182,746 |
| Adult Health | 7,084 | 2,017 | 16,283 | 11,638 | 15,667 | 20,312 | 16,442 |
| Other | 22 | 26 | 81 | 163 | 179 | 97 | 163 |
| Total Americas | 42,893 | 45,521 | 186,965 | 153,834 | 203,748 | 236,879 | 199,351 |
| Total | 173,841 | 131,961 | 578,947 | 559,467 | 747,077 | 766,557 | 767,083 |
| Jul–Sep | Jul–Sep | Jan–Sep | Jan–Sep | Jan–Dec | |
|---|---|---|---|---|---|
| Date of recognition Performance obligations met on specific date (Product | |||||
| sales) | 2021 | 2020 | 2021 | 2020 | 2020 |
| Paediatrics | 128,927 | 98,248 | 447,646 | 433,193 | 570,829 |
| Adult Health | 39,220 | 26,944 | 105,483 | 106,079 | 148,635 |
| Other | 713 | 481 | 2,057 | 1,533 | 2,027 |
| Total | 168,860 | 125,673 | 555,186 | 540,805 | 721,491 |
| Performance obligations met over time (Royalty) | |||||
| Paediatrics | 1,903 | 3,606 | 5,935 | 10,304 | 12,282 |
| Adult Health | 2,869 | 2,397 | 16,211 | 7,798 | 12,551 |
| Other | 209 | 284 | 1,615 | 560 | 753 |
| Total | 4,981 | 6,287 | 23,761 | 18,662 | 25,586 |
| Total | 173,841 | 131,961 | 578,947 | 559,467 | 747,077 |
| (Amounts in SEK 000s) | Jan–Sep 2021 |
Jan–Sep 2020 |
Jan–Dec 2020 |
|---|---|---|---|
| Opening balance | 1,746,245 | 507,874 | 507,874 |
| New issue, net | - | - | 1,130,512 |
| New issue warrants | 4,989 | - | - |
| Dividend | -68,870 | -65,012 | -65,012 |
| Provision to Foundation to Prevent Antibiotic Resistance | -2,800 | -2,800 | -2,800 |
| Comprehensive income for the period | 159,248 | 137,498 | 175,671 |
| Closing balance | 1,838,812 | 577,560 | 1,746,245 |
| A shares |
B shares | Share capital |
No. of votes | Capital (%) | Votes (%) | ||
|---|---|---|---|---|---|---|---|
| 1 | Annwall & Rothschild Investments AB | 740,668 | 100,000 | 840,668 | 7,506,680 | 4.2% | 27.9% |
| 2 | EQT | 1,625,000 | 1,625,000 | 1,625,000 | 8.0% | 6.0% | |
| 3 | Fjärde AP-fonden | 1,624,000 | 1,624,000 | 1,624,000 | 8.0% | 6.0% | |
| 4 | Premier Miton Investors | 1,274,376 | 1,274,376 | 1,274,376 | 6.3% | 4.7% | |
| 5 | Handelsbanken Fonder | 1,163,470 | 1,163,470 | 1,163,470 | 5.8% | 4.3% | |
| 6 | TIN Fonder | 668,835 | 668,835 | 668,835 | 3.3% | 2.5% | |
| 7 | Cargill Inc | 600,000 | 600,000 | 600,000 | 3.0% | 2.2% | |
| 8 | Tredje AP-fonden | 494,909 | 494,909 | 494,909 | 2.5% | 1.8% | |
| 9 | AMF Pension & Fonder | 403,197 | 403,197 | 403,197 | 2.0% | 1.5% | |
| 10 | Juno Investment Partners | 371,038 | 371,038 | 371,038 | 1.8% | 1.4% | |
| Other shareholders | 11,130,969 | 11,130,969 | 11,130,969 | 55.1% | 41.4% | ||
| Total | 740,668 | 19,455,794 | 20,196,462 | 26,862,474 | 100% | 100% |
| Jan–Sep 2021 | Jan–Sep 2020 | Jan–Dec 2020 | |
|---|---|---|---|
| Net sales, SEK 000s | 578,947 | 559,467 | 747,077 |
| Growth of net sales | 3% | 0% | -3% |
| Operating profit, SEK 000s | 200,647 | 182,900 | 228,150 |
| Profit after tax, SEK 000s | 157,998 | 141,263 | 179,730 |
| Return on equity | 9% | 26% | 16% |
| Return on capital employed | 11% | 33% | 20% |
| Capital employed, SEK 000s | 1,850,030 | 587,899 | 1,757,557 |
| Number of shares, thousands | 20,196 | 17,336 | 20,196 |
| Average number of shares before dilution, thousands 1) | 20,196 | 17,474 | 17,855 |
| Average number of shares after dilution, thousands 1) | 20,196 | 17,474 | 17,855 |
| Earnings per share before dilution, SEK 1) 2) | 7.82 | 8.08 | 10.07 |
| Earnings per share after dilution, SEK 1) 2) | 7.82 | 8.08 | 10.07 |
| Equity per share, SEK 1) | 91.05 | 33.05 | 97.80 |
| Equity/assets ratio | 93% | 81% | 91% |
| Operating margin | 35% | 33% | 31% |
| Profit margin | 35% | 33% | 30% |
| Average number of employees | 158 | 157 | 157 |
1) A bonus issue element from the 2020 new issue has been taken into account in the calculation of earnings per share before and after dilution and equity per share, which means that comparative figures have been recalculated.
2) Key ratio defined according to IFRS.
A list of definitions of key ratios reported in the consolidated financial statements is provided on page 66 of BioGaia's annual report for 2020. In this report, BioGaia reports information used by Executive Management to assess the Group's development. Some of the key ratios presented are not defined according to IFRS. The company is of the opinion that these metrics provide valuable complementary information to stakeholders and the company's management since they contribute to evaluation of relevant trends and the company's performance. Since not all companies calculate key ratios in the same manner, these are not always comparable to metrics used by other companies. These key ratios should therefore not be seen as a replacement for metrics defined according to IFRS. With effect from 3 July 2016, ESMA's guidelines on alternative performance measures are applied which means extended disclosure requirements regarding key ratios not defined according to IFRS. A reconciliation of key ratios that BioGaia considers relevant according to these guidelines is provided below.
| (Amounts in SEK 000s) | |||
|---|---|---|---|
| Jan–Sep | Jan–Sep | Jan–Dec | |
| Return on equity | 2021 | 2020 | 2020 |
| Profit attributable to owners of the Parent Company (A) | 157,998 | 141,263 | 179,730 |
| Equity attributable to owners of the Parent Company | 1,838,810 | 577,558 | 1,746,243 |
| Average equity attributable to owners of the Parent Company (B) | 1,792,527 | 542,715 | 1,127,058 |
| Return on equity (A/B) | 9% | 26% | 16% |
| Return on capital employed | |||
| Operating profit | 200,647 | 182,900 | 228,150 |
| Financial income | 64 | 109 | 155 |
| Profit before net financial items + financial income (A) | 200,711 | 183,009 | 228,306 |
| Total assets | 1,967,688 | 711,867 | 1,913,282 |
| Interest-free liabilities | -117,658 | -123,968 | -155,725 |
| Capital employed | 1,850,030 | 587,899 | 1,757,557 |
| Average capital employed (B) | 1,803,794 | 553,056 | 1,137,885 |
| Return on capital employed (A/B) | 11% | 33% | 20% |
| (Amounts in SEK 000s) | 30 Sep | 30 Sep | 31 Dec |
|---|---|---|---|
| Equity/assets ratio | 2021 | 2020 | 2020 |
| Equity (A) | 1,838,812 | 577,560 | 1,746,245 |
| Total assets (B) | 1,967,688 | 711,867 | 1,913,282 |
| Equity/assets ratio (A/B) | 93% | 81% | 91% |
| Operating margin | |||
| Operating profit (A) | 200,647 | 182,900 | 228,150 |
| Net sales (B) | 578,947 | 559,467 | 747,077 |
| Operating margin (A/B) | 35% | 33% | 31% |
| Profit margin | |||
| Profit before tax (A) | 200,078 | 182,447 | 227,583 |
| Net sales (B) | 578,947 | 559,467 | 747,077 |
| Profit margin (A/B) | 35% | 33% | 30% |
BioGaia AB (publ) Interim management statement, January – September 2021 14
| Equity per share | |||
|---|---|---|---|
| Equity attributable to owners of the Parent Company (A) | 1,838,810 | 577,558 | 1,746,243 |
| Average number of shares, before and after dilution (B) | 20,196 | 17,474 | 17,855 |
| Equity per share (A/B) | 91.05 | 33.05 | 97.80 |
| Paediatrics Adult Health |
Other | Total | |||||||
|---|---|---|---|---|---|---|---|---|---|
| (Amounts in SEK 000s) | Jul–Sep 2021 |
Jan– Sep 2021 |
Jul–Sep 2021 |
Jan– Sep 2021 |
Jul–Sep 2021 |
Jan– Sep 2021 |
Jul–Sep 2021 |
Jan– Sep 2021 |
|
| A | Description Previous year's net sales according to the average rate |
101,854 | 443,497 | 29,341 | 113,878 | 766 | 2,093 | 131,962 | 559,467 |
| B | Net sales for the year according to the average rate | 130,830 | 453,581 | 42,089 | 121,694 | 922 | 3,672 | 173,841 | 578,947 |
| C | Recognised change (B-A) | 28,976 | 10,084 | 12,748 | 7,816 | 156 | 1,579 | 41,879 | 19,480 |
| Percentage change (C/A) | 28% | 2% | 43% | 7% | 20% | 75% | 32% | 3% | |
| D | Net sales for the year according to the previous year's average rate (D) |
134,322 | 491,241 | 43,204 | 131,188 | 922 | 3,671 | 178,448 | 626,100 |
| E | Foreign exchange effects (C-F) | -3,491 | -37,660 | -1,115 | -9,495 | 0 | 1 | -4,606 | -47,154 |
| Percentage change (E/A) | -3% | -8% | -4% | -8% | 0% | 0% | -3% | -8% | |
| F | Organic change (D-A) | 32,467 | 47,744 | 13,863 | 17,311 | 156 | 1,578 | 46,485 | 66,634 |
| Organic change per cent (F/A) | 32% | 11% | 47% | 15% | 20% | 75% | 35% | 12% |
| Average key exchange rates | Jul–Sep 2021 |
Jul–Sep 2020 |
Jan–Sep 2021 |
Jan–Sep 2020 |
Jan–Dec 2020 |
|---|---|---|---|---|---|
| EUR | 10.16 | 10.36 | 10.14 | 10.60 | 10.54 |
| USD | 8.56 | 8.88 | 8.41 | 9.51 | 9.27 |
| JPY | 0.0788 | 0.0836 | 0.0782 | 0.0874 | 0.0862 |
| Closing date key exchange rates | 30 Sep 2021 |
30 Sep 2020 |
31 Dec 2020 |
|---|---|---|---|
| EUR | 10.20 | 10.54 | 10.04 |
| USD | 8.79 | 8.99 | 8.19 |
| JPY | 0.0786 | 0.0851 | 0.0792 |
| Pledged assets and contingent liabilities | GROUP | |||
|---|---|---|---|---|
| (Amounts in SEK 000s) | 30 Sep 2021 |
31 Dec 2020 |
||
| Floating charges | 0 | 0 | ||
| Contingent liabilities | None | None |
8:00 a.m. CEST Interim management statement 1 January – 31 March 2022 6 MAY
2022
8:00 a.m. CEST Interim Report 1 January – 30 June 2022 22 JUL
8:00 a.m. CEST Interim management statement 1 January – 30 September 2022 21 OCT
Stockholm, 21 October 2021
Isabelle Ducellier CEO
This interim management statement has not been audited.
Q3
2021
BioGaia is a Swedish world-leading probiotic company that has been at the forefront of microbiome research for more than 30 years. BioGaia develops, markets and sells probiotic products with documented health benefits. The company operates throughout the value chain partly through the company and partly through global networks of leading, independent researchers and specialists, production experts and local distribution partners.
BioGaia's products contain strains of the lactic acid bacterium L. reuteri (Limosilactobacillus reuteri, formerly known as Lactobacillus reuteri). Results from clinical studies with BioGaia's probiotic strains have been published in more than 200 articles in scientific journals, proving that they are effective and safe in children and adults. By developing and offering clinically-proven and user-friendly probiotic products, BioGaia wants to contribute to improved global health.
BioGaia has 159 employees, of whom 128 are based in Sweden (Stockholm, Lund, Eslöv and Gothenburg), two in the USA, two in Singapore and 27 in Japan. The class B shares of the Parent Company BioGaia AB are quoted on the Mid Cap List of Nasdaq OMX Nordic Exchange Stockholm.
BioGaia's business model is based on long-term collaboration with international networks within research, production and distribution.
BioGaia's revenue comes mainly from the sale to distributors of drops, tablets and capsules for gut health, oral rehydration solution (ORS), lozenges for oral health and capsules for bone health. Revenue is also earned from the sale of bacterial cultures to be used in licensee products (such as infant formula and dairy products), as well as royalties for the use of L. reuteri in licensee products.
The products are sold through pharmaceutical and nutrition companies in over 100 countries.
BioGaia holds patents for the use of certain strains of L. reuteri and certain packaging solutions in all major markets.
BioGaia launched its own consumer brand at the beginning of 2006. Today a number of distribution partners sell finished products under the BioGaia brand in a large number of markets. One central part of BioGaia's strategy is to increase the proportion of sales consisting of BioGaia-branded products. Of products (drops, tablets for gut and oral health, oral rehydration, etc.) sold in 2020, 77% (71%) were sold under the BioGaia brand including co-branding.
Some of BioGaia's distributors sell finished consumer products under their own brand names. On these products, the BioGaia brand is shown on the consumer package since BioGaia is both the manufacturer and licensor.
BioGaia's licensees add L. reuteri culture to their products and sell these under their own brand names. On these products, the BioGaia brand is most often shown on the package as the licensor/patent holder.
BioGaia's strains of L. reuteri are among the most studied probiotics in the world, especially in young children.
Studies have been performed on:
BioGaia AB Box 3242 SE-103 64 STOCKHOLM Street address: Kungsbroplan 3, Stockholm Telephone: +46 8 555 293 00, Corporate identity no. 556380-8723, www.biogaia.com
Building tools?
Free accounts include 100 API calls/year for testing.
Have a question? We'll get back to you promptly.